2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Tomi Jun, MD, Stanford University School of Medicine, discusses results of a multi-center study investigating patients with cyptogenic hepatocellular carcinoma (HCC).
Tomi Jun, MD, Stanford University School of Medicine, discusses results of a multi-center study investigating patients with cyptogenic hepatocellular carcinoma (HCC).
It was confirmed in a large cohort of 4000 patients with cyptogenic HCC, that one-third did not have cirrhosis, explains Jun. It was also discovered that this population presents with a later stage of disease and often with more advanced tumors.
According to Jun, this suggests that if there was better early detection, these patients might have better survival rates.
Related Content: